Company
German drug maker
Every investor coverage indicates participated in a round Grünenthal raised.
Companies Grünenthal acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Chris Bremer | Executive Vice President for Early Products and Commercial Opportunities (former) | Biotech Dispatch (1 Oct 2026), Biotech Dispatch (7 Sep 2026) |
Stories naming Grünenthal. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Neurizon Therapeutics appoints Chris Bremer as CEO while interim executive chairman Sergio Duchini becomes non-executive chairman, with the company's ALS drug awaiting Phase 2/3 trial results in 2027.
Neurizon Therapeutics, a Melbourne biotech developing an ALS treatment, has appointed industry veteran Dr Chris Bremer as CEO as its lead drug NUZ-001 heads toward Phase 2/3 trial results in 2027.